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Abstract
Background: Primary pancreatic leiomyosarcoma is a rare pancreatic malignancy; the clinical presentation and
treatment is not well-characterized. Further, the molecular mechanisms underlying its pathogenesis are not known.
We report a patient with pancreatic stromal tumor that progressed to primary pancreatic leiomyosarcoma with
hepatic and peritoneal metastases.
Case presentation: A 54-year-old woman was found to have pancreatic and hepatic tumor masses on routine
health checkup. Owing to the difficulty in performing biopsy, this patient underwent open operation. Histopathological
examination of pancreatic and liver biopsy specimen demonstrated spindle cells with nuclear mitoses.
Immunohistochemical examination showed positive staining for Cluster of Differentiation117 (+) and negative
staining for S-100 (-) and Smooth Muscle Actin (-). Thus, the patient was diagnosed as a case of advanced
pancreatic stromal tumor with liver metastases. After surgery, treatment with oral imatinib mesylate combined
with thymosin injection therapy was prescribed. Follow-up examination at 13-months revealed multiple nodular
masses in liver and right peritoneum. The patient underwent a second surgery. Liver biopsy and the resected
peritoneal specimen showed positive staining for Discovered On Gastrointestinal tumor-1(weak +), Actin (+),
Smooth Muscle Actin (+) and negative staining for Cluster of Differentiation117 (-) Cluster of Differentiation34 (-) and
S-100 (-). Histopathological examination showed spindle cells with nuclear mitoses. The final diagnosis was primary
pancreatic leiomyosarcoma, transdifferentiating from pancreatic stromal tumor, with liver and peritoneal metastases.
Conclusions: Surgery is the first line treatment for primary pancreatic leiomyosarcoma and extra-gastrointestinal
stromal tumors. In the present case, radical resection was not performed owing to hepatic metastases. Palliative
treatment with radioactive 125I ion implantation and microwave coagulation therapy was administered. However,
the long-term therapeutic effect needs to be assessed in future.
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Background
Primary pancreatic leiomyosarcoma is a rare pancreatic
tumor, which accounts for approximately 0.1% of all
primary pancreatic malignant neoplasms [1]. However,
very little is known about the tumor [2]. In this case
report, we present our experience with a case of
pancreatic stromal tumor, which progressed to primary
pancreatic leiomyosarcoma with liver metastases.
Case presentation
A 54-year-old woman was found to have pancreatic and
hepatic tumor masses on a routine health check-up.
Abdominal ultrasound showed a clearly delineated
hypoechoic mass (2.4 cm × 2.0 cm) in the IVa segment
of the left hepatic lobe, near the diaphragmatic dome
and left hepatic vein. A pancreatic mass (4.6 × 2.2 cm)
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located on the dorsal aspect of pancreatic body, in front
of splenic vein, was also observed (Additional file 1:
Figure S1A-B). Hepatic contrast ultrasound revealed a
significant increase in size of the mass in the left liver
lobe during the arterial phase. Abdominal computed
tomography (CT) revealed a heterogeneous low-density
mass with an ill-defined swelling in the pancreas
(Additional file 1: Figure S1C-F). Owing to the diffi-
culty in performing biopsy, open operation was per-
formed. Intraoperative macroscopic findings included
a gray hard pancreatic mass in the middle segment of
the pancreas and a mass in the left liver lobe. Fine
needle aspiration cytology showed atypical cells. The
diagnosis of pancreatic cancer could not be excluded.
Radioactive 125I ion implantation for the pancreatic tumor
mass, and microwave coagulation therapy for the hepatic
lesions was administered. Histopathological examination
of pancreatic and liver biopsy specimens demonstrated
spindle cells with nuclear mitoses (1-2 per 50× high
power field) (Fig. 1a). Immunohistochemical examination
showed positive staining for Vimentin (+) (Fig. 1b), Dis-
covered On Gastrointestinal tumor (DOG)-1(+) (Fig. 1c),
Cluster of Differentiation (CD) 117 (+) (Fig. 1d), 60%Ki67
(+), and negative staining for S-100 (-), CD34 (-), Cytoker-
atin (-), Smooth Muscle Actin (SMA) (-) (Fig. 1e), Desmin
(-), and EMA (-). A diagnosis of advanced pancreatic stro-
mal tumor with liver metastases was made.
The patient recovered well after surgery. Oral imatinib
mesylate (300 mg once a day) plus thymosin subcutane-
ous injection (1.6 mg twice a week for 4 weeks) were
prescribed. Follow-up CT and ultrasound examinations
at 6 and 10 months showed no signs of tumor growth in
the pancreas and liver (Additional file 2: Figure S2A-D).
Repeat CT at the 13-month follow-up revealed multiple
hepatic nodular masses in IVa segment, V segment and
the border of V and VI segments (size 0.3–0.5 cm) and
right peritoneum (Additional file 2: Figure S2E-F).
A second surgery was performed to remove the periton-
eal mass and to obtain liver biopsy. During operation,
microwave coagulation therapy for liver lesions was re-
administered. Immunohistochemical study of liver biopsy
specimen and the resected peritoneal specimen showed
positive staining for DOG-1 (weak +), Actin (+), SMA (+)
(Fig. 2c and f), Caldesmon (+), Ki67 (30% +) and negative
staining for CD117 (-) (Fig. 2b and e), Desmin (-), CD34
(-) and S-100 (-). Histopathological examination showed
spindle cells with nuclear mitoses (14–20 per 10 high
power fields) (Fig. 2a and d). Spindle shaped malignant
cells with nuclear mitoses (2–5 per 10 high power fields)
were also observed in the liver biopsy specimen.
The c-KIT and platelet-derived growth factor receptor
α genes were sequenced. Wild-type variants were de-
tected in exons 9, 11, 13 and 17 of the c-KIT gene and
of exons 12 and 18 of the platelet-derived growth factor
receptor α gene. The woman was finally diagnosed as a
case of primary pancreatic leiomyosarcoma, which trans-
differentiated from pancreatic stromal tumor, with liver
and peritoneal metastases.
Leiomyosarcoma and its subtype, primary pancreatic
leiomyosarcoma, have rarely been reported. The esti-
mated worldwide incidence of PLMS is 1-2/100,000
population [3]. Baylor et al. found only five cases of pri-
mary pancreatic leiomyosarcoma in a study of 5057 pa-
tients with pancreatic cancer [4]. In 1951, Ross et al.
reported the first case of primary pancreatic leiomyosar-
coma [5]; since then, only 71 such cases are on record
[3]. The gastrointestinal stromal tumor mostly arises
from Cajal or its precursor cells [6, 7]. Histological and
immunogenic properties of extra-gastrointestinal stro-
mal tumors are similar to those of gastrointestinal
Fig. 1 Histopathological (a) and immunohistochemical examination of the first biopsy specimen (b, c, d, e) showing Vimentin (+), DOG-1 (+),
CD117 (+), SMA (-), respectively
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stromal tumor, but the former originates from abdom-
inal or retroperitoneal soft tissues [1]. To the best of our
knowledge, this is the first report of a case of extra-
gastrointestinal stromal tumor which progressed to pri-
mary pancreatic leiomyosarcoma.
The clinical manifestations are non-specific [8]. Our pa-
tient was asymptomatic prior to the diagnosis. The radio-
logical examination for primary pancreatic leiomyosarcoma
has low specificity [2]. Endoscopic ultrasonography-guided
biopsy does facilitate a preoperative diagnosis; however, re-
peated sampling may be needed [6, 7].
Histological and immunohistochemical examination is
the gold standard for diagnosis. In a study of 12 patients
with primary pancreatic leiomyosarcoma, presence of
more than 10/50 nuclear mitotic figures per high power
field was associated with poor survival [9]. Xu et al. re-
ported a median survival rate of 48 months; survival
rates at 1, 3, 5 and 10 year were 66.6, 51.2, 43.9 and
29.3%, respectively [3]. Non-radical surgery and infiltra-
tion of surrounding organ and vessels were independ-
ently associated with poor prognosis. Another study
demonstrated the presence of spindle shaped smooth
muscle-like cells in primary pancreatic leiomyosarcoma,
and IHC markers SMA (+), MSA (+), Desmin (+),
CD117 (-), HMB45 (-), DOG-1 (-), CD34 (-) [10], while
gastrointestinal stromal tumors were characterized by
CD117 (+), CD34 (+), DOG-1 (+), SMA (-), Desmin (-),
S-100 (-) [11].
Positive staining for CD117 may help differentiate be-
tween primary between extra-gastrointestinal stromal tu-
mors and primary pancreatic leiomyosarcoma. In our
study, initial immunohistochemical study of liver and
pancreas specimens showed CD117 (+), while that of
liver biopsy and peritoneal specimens at second- surgery
detected CD117 (-) and SMA(+), which is indicative of
transformation of extra-gastrointestinal stromal tumors
to primary pancreatic leiomyosarcoma. Imatinib has
been reported to induce differentiation of gastrointes-
tinal stromal tumors into leimyoscarcoma [11], which
may have contributed to the transdifferentiation ob-
served in our patient.
Conclusion
Surgery is the first line treatment for primary pancreatic
leiomyosarcoma and extra-gastrointestinal stromal tu-
mors. Radical resection either alone or in combination
Fig. 2 Histopathological and immunohistochemical examination of liver biopsy specimen (a-c) and surgically resected peritoneal deposits (d-f)
showing spindle cells with nuclear mitoses, CD117 (-), SMA (+) respectively
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with protein receptor tyrosine kinase (RTK) inhibitor is
associated with prolonged survival [12]. Radiofrequency
ablation and liver transplantation are other potential
therapeutic options in such patients; however, definitive
evidence of their clinical efficacy is yet to be obtained. In
the present study, the patient was diagnosed as pancre-
atic cancer with liver metastases after the first surgery.
Thus, radical resection was not performed, and instead
palliative treatment (radioactive 125I ion implantation
and microwave coagulation therapy) was administered.
In our patient, no obvious changes were observed in the
pancreatic and hepatic tumors at 6 and 10-month
follow-up. Taken together, we conclude that gastrointes-
tinal stromal tumors with liver metastasis are amenable
to local treatment plus imatinib therapy. The therapeutic
efficacy of radioactive 125I ion implantation is yet to be
documented. In addition, the long-term therapeutic out-
comes need to be assessed in future.
Additional files
Additional file 1: Figure S1. Preoperative abdominalultrasound (A, B)
and computed tomography radiographs (C, D, E, F) showing tumor
masses in liver and pancreas. (TIF 2890 kb)
Additional file 2: Figure S2. Follow-up ultrasound and abdominal CT
radiographs at 6-month (A), 10-month (B, C, D) and 13-month follow-up
(E, F) examination. CT, computed tomography. (TIF 2862 kb)
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